CIK 0001053691 · Non-accelerated filer<br>Smaller reporting company
CervoMed Inc.
Sign in to watch- Ticker
- CRVO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300645032
- Phone
- (617) 744-4400
- Business address
- 20 PARK PLAZA, SUITE 424, BOSTON, MA, 02116
- Former names
- Diffusion Pharmaceuticals Inc., RestorGenex Corp, Stratus Media Group, Inc, FERIS INTERNATIONAL, INC., TITAN MOTORCYCLE CO OF AMERICA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-22 | Blackburn Kelly EVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +19,100 | 19,100 | ||
| 2026-10-22 | De Rosch Mark EVP, RA and GA and PgM | Grant or award · Stock Option (Right to Buy) | +19,100 | 19,100 | ||
| 2026-10-22 | Winton Matthew Chief Commercial and Business | Grant or award · Stock Option (Right to Buy) | +19,100 | 19,100 | ||
| 2026-06-11 | BOGER JOSHUA S Director | Purchase | +955,414 | $3.14 | $3.0M | 1,795,865 |
| 2026-06-11 | BOGER JOSHUA S Director | Purchase · Series B Warrants | +955,414 | 955,414 | ||
| 2026-06-11 | BOGER JOSHUA S Director | Purchase · Series C Warrants | +955,414 | 955,414 | ||
| 2026-06-08 | ZAVRL FRANK Director | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-06-08 | Sabbagh Marwan Director | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-06-08 | Quigley David Director | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-06-08 | Poulton Jeffrey V. Director | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-06-08 | Hollingsworth Jane H Director | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-06-08 | Gregoire Sylvie Director | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-06-08 | BOGER JOSHUA S Director | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-06-08 | ALAM JOHN J CEO & President | Grant or award · Stock Option (Right to Buy) | +8,150 | 8,150 | ||
| 2026-02-11 | Winton Matthew Chief Commercial and Business | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-02-11 | Gregoire Sylvie Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2026-02-11 | ELDER WILLIAM ROBERT CFO, GC & Secretary | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-02-11 | De Rosch Mark EVP, RA and GA and PgM | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-02-11 | Blackburn Kelly EVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-02-11 | ALAM JOHN J CEO & President | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 |
Page 1 of 17 · 321 trades